Rev Esp Quimioter 2023;36(Suppl.1):15-17

Risk of severe COVID in solid organ transplant recipients

PABLO BARREIRO, FRANCISCO JAVIER CANDEL, MARÍA DEL MAR CARRETERO, JESÚS SAN ROMÁN

Published: 24 November 2023

http://www.doi.org/10.37201/req/s01.04.2023

ABSTRACT
Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.

Rev Esp Quimioter 2023; 36(Suppl.1):15-17 [Full-text PDF]